AstraZeneca’s Olaparib Clears FDA For Later Therapy Line In Ovarian Cancer
This article was originally published in The Pink Sheet Daily
AstraZeneca’s Lynparza was rejected as a maintenance therapy after second-line treatment by an FDA advisory committee, but landed accelerated approval for heavily pretreated relapsed patients, based on data not considered in the initial advisory committee review.
You may also be interested in...
Tesaro's niraparib has an advantage over other PARP inhibitors in that it has been tested successfully in Phase III for ovarian cancer patients with and without BRCA mutations, but AstraZeneca thinks it may have a case for broad labeling without pivotal data in this population.
When Phase III clinical trial failures happen it is a painful blow – to the drug manufacturer, to investors and to patients. Scrip takes a look at some of the biggest Phase III surprises since 2010.
AstraZeneca has an ambitious agenda to become a leader in oncology. The company’s notably improved pipeline is broad, but winning will require AstraZeneca to come from behind to uncover the best combinations ahead of the competition.